Search

EHA’s advocacy for hematology continues

The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:

Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more

Genome sequencing of thousands of patients with rare blood disorders

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.

Read more

What an EHA Bilateral Collaborative Grant supports

Our EHA Bilateral Collaborative Grant supports basic and translational lab-based research in hematology. To reflect the collaborative spirit of the grant, the budget must be divided 50:50 between the two PIs.

Read more

Cancer Medicines Forum workshop April 5: a way forward for treatment optimization

The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).

Read more

What an EHA Kick-off Grant supports

Our EHA Kick-off Grant supports basic and translational lab-based research in hematology. Costs that can be supported by an EHA Kick-off Grant
Lab consumables. Max € 5,000 for equipment, if properly justified.

Read more

EHA Innovation Grant

The call for applications is closed. The EHA Innovation Grant is intended to encourage and support the creation of consortia and the generation of preliminary data to facilitate applying for larger funding opportunities.

Read more